These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8733988)

  • 1. Penetration of loracarbef into the maxillary sinus: a pharmacokinetic assessment.
    Stenquist M; Olen L; Jannert M; Näslund L; Zeckel ML
    Clin Ther; 1996; 18(2):273-84. PubMed ID: 8733988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice-daily dosing of loracarbef 200 mg versus 400 mg in the treatment of patients with acute maxillary sinusitis.
    Zeckel ML; Johns D; Masica DN; Farlow D
    Clin Ther; 1995; 17(2):214-30. PubMed ID: 7614522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily].
    Jehl F; Klossek JM; Peynegre R; Serrano E; Castillo L; Bobin S; Desprez D; Renault C; Neel V; Rouffiac E; Borie C
    Presse Med; 2002 Oct; 31(34):1596-603. PubMed ID: 12426976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loracarbef (LY 163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis.
    Sydnor TA; Scheld WM; Gwaltney J; Nielsen RW; Huck W; Therasse DG
    Ear Nose Throat J; 1992 May; 71(5):225-32. PubMed ID: 1505371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration.
    Lopez Sisniega J; Profant M; Kostrica R; Waskin H
    Clin Ther; 2007 Aug; 29(8):1632-44. PubMed ID: 17919545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetration of pefloxacin into maxillary sinus cavity and nasal secretions.
    Petrikkos G; Goumas P; Moschovakis E; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1992 Sep; 11(9):828-31. PubMed ID: 1468421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loracarbef versus doxycycline in the treatment of acute bacterial maxillary sinusitis. Scandinavian Study Group.
    J Antimicrob Chemother; 1993 Jun; 31(6):949-61. PubMed ID: 8360132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of loracarbef.
    DeSante KA; Zeckel ML
    Am J Med; 1992 Jun; 92(6A):16S-19S. PubMed ID: 1621740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute bacterial maxillary sinusitis: results of U.S. and European comparative therapy trials.
    Nielsen RW
    Am J Med; 1992 Jun; 92(6A):70S-73S. PubMed ID: 1621749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Penetration of erythromycin stearate into maxillary sinus mucosa and secretion in chronic maxillary sinusitis.
    Paavolainen M; Kohonen A; Palva T; Renkonen OV
    Acta Otolaryngol; 1977; 84(3-4):292-5. PubMed ID: 199040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice-daily dosing of loracarbef 15 mg/kg versus 30 mg/kg in the treatment of children with acute sinusitis.
    Balatsouras DG; Korres S; Rallis E; Eliopoulos P; Ferekidis E
    Drugs Exp Clin Res; 2005; 31 Suppl():1-5. PubMed ID: 16444905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study of cefaclor in chronic maxillary sinusitis.
    Goumas PD; Moschovakis E; Petrikkos G; Giamarellou E
    J Chemother; 1992 Jun; 4(3):155-8. PubMed ID: 1517808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azithromycin concentrations in sinus fluid and mucosa after oral administration.
    Karma P; Pukander J; Penttilä M
    Eur J Clin Microbiol Infect Dis; 1991 Oct; 10(10):856-9. PubMed ID: 1662632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefotiam concentrations in the sinus fluid of patients with chronic sinusitis after administration of cefotiam hexetil.
    Cherrier P; Tod M; Le Gros V; Petitjean O; Brion N; Chatelin A
    Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):211-5. PubMed ID: 8508820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis.
    Ambrose PG; Anon JB; Bhavnani SM; Okusanya OO; Jones RN; Paglia MR; Kahn J; Drusano GL
    Diagn Microbiol Infect Dis; 2008 May; 61(1):13-20. PubMed ID: 18313879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetration of cefetamet pivoxil and cefuroxime axetil into the maxillary sinus mucosa at steady state.
    Stoeckel K; Harell M; Dan M
    Antimicrob Agents Chemother; 1996 Mar; 40(3):780-3. PubMed ID: 8851611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical localization of cytokines and cell adhesion molecules in maxillary sinus mucosa in chronic sinusitis.
    Nonoyama T; Harada T; Shinogi J; Yoshimura E; Sakakura Y
    Auris Nasus Larynx; 2000 Jan; 27(1):51-8. PubMed ID: 10648069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penetration of antibiotics in diseased antral mucosa.
    Westergren V; Nilsson M; Forsum U
    Arch Otolaryngol Head Neck Surg; 1996 Dec; 122(12):1390-4. PubMed ID: 8956757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic disposition of loracarbef in healthy young men and women at steady state.
    Sitar DS; Hoban DJ; Aoki FY
    J Clin Pharmacol; 1994 Sep; 34(9):924-9. PubMed ID: 7983236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of treatment on maxillary sinus and nasal nitric oxide concentrations in patients with nosocomial maxillary sinusitis.
    Degano B; Génestal M; Serrano E; Rami J; Arnal JF
    Chest; 2005 Sep; 128(3):1699-705. PubMed ID: 16162777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.